Gefitinib + gemcitabine + carboplatin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer Metastatic
Conditions
Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation
Trial Timeline
Dec 1, 2014 → Oct 1, 2017
NCT ID
NCT02299765About Gefitinib + gemcitabine + carboplatin
Gefitinib + gemcitabine + carboplatin is a approved stage product being developed by AstraZeneca for Non-small Cell Lung Cancer Metastatic. The current trial status is terminated. This product is registered under clinical trial identifier NCT02299765. Target conditions include Non-small Cell Lung Cancer Metastatic, EGFR Activating Mutation.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer Metastatic were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02299765 | Approved | Terminated |
| NCT00264498 | Phase 2 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer Metastatic